Omada is significantly expanding its digital platform to include prescribing and medication management for anti-obesity medications, a major strategic initiative to meet market demand. This requires new technology infrastructure, provider partnerships, and processes to support a nationally scalable prescribing model.
Filing excerpt
In addition, we recently announced the capability to prescribe GLP-1 therapies and other anti-obesity medications (“AOMs”) as an extension of our GLP-1 support offerings, reflecting our proactive approach to evolving care models and meeting customer needs, while continuing to innovate on traditional care protocols.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10kdigitalTransformationGet every 10-K signal for Omada Health and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Omada Health this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/fb219ee1-3333-4cf2-8eef-536ddd114fe5 returns this record as JSON. POST /v1/companies/enrich returns every signal for omadahealth.com.
{
"signal_id": "fb219ee1-3333-4cf2-8eef-536ddd114fe5",
"signal_type": "sec-10k",
"signal_subtype": "digitalTransformation",
"detected_at": "2026-03-10T06:52:52.225+00:00",
"company": {
"name": "Omada Health",
"domain": "omadahealth.com"
},
"data": {
"detail": "Omada is significantly expanding its digital platform to include prescribing and medication management for anti-obesity medications, a major strategic initiative to meet market demand. This requires new technology infrastructure, provider partnerships, and processes to support a nationally scalable prescribing model.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Launching new GLP-1 and AOM prescribing capabilities in the current year.",
"excerpts": "In addition, we recently announced the capability to prescribe GLP-1 therapies and other anti-obesity medications (“AOMs”) as an extension of our GLP-1 support offerings, reflecting our proactive approach to evolving care models and meeting customer needs, while continuing to innovate on traditional care protocols.",
"relevance": 0.85,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1611115/000162828026015637/omda-20251231.htm",
"filing_date": "2026-03-06",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Multi-year tech investment",
"signal_category": "strategic",
"technologies_mentioned": [
"telehealth"
]
}
}
curl https://signals.autobound.ai/v1/signals/fb219ee1-3333-4cf2-8eef-536ddd114fe5 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"omadahealth.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.